2023-12-31-accounts

MPA

HPV AND ANAL ED CEMBER 2 RefqrqnL* and mminis1rnti￿ Detslls Roport of the Trustees 2-17 llnde￿ndent Examlners, report 18 Stat¢nxrt of An•￿1•1 AIX1v￿ 19 B•l•nce Sheet 20 Ststsment of Cash Flow Notes to the Flnandbl Statemnts 22-29

FOR THE YEAR EMBER 2 Reference and Admlnlstratlve Detslls For the Year ended 31 December 2023 LEGAL AND ADMINISTRAllVE INFORMATION TRUSTEES C Ajmada J Alm&Ja T Amada REGisfERED OFFIC 128 fjty Road London ECIV 2NX REGISTERED COMPANY NUMBER 07955451 (EnglarKI arKI Wales) REGJsfERED CHARITY NUMBER 1147457 INDEPENDEKr EXAMINER Knox Crcpr*r LLP 65 Leadenhall Street LoTrJon EC3A 2AD sOUc￿oRs Strjne Klng 16 St John's La London ECIM 48S BANKERS 16 KlrKJ Street Covent Garden London WC2E 8JF

EHPV NCER F UND qi The and Anal CarKer Fourmlation Linwtuj ￿ a UINtsJ ￿ngd￿ (UK) subsdiary of Tr HPV and Anal Can￿r FcyJndatM in the Unrted Ststes of ATrrica lu￿) Ictsrity EIN: 27-3217520). whth e5tstAshed April 2010. AII work undertaken by the UK FoJ￿jat10n is in CollabJratiC￿ WTth Its parenL The HW and Anal QirKer Foundavon Llmtted bs a chbrltsNe ccrfnpany by shales. Inc￿)Drated In the UK on the 20th February 2012 and regi#ereO os a thJrlty on the 25th May 2012. The company was estsNisFd through its Articks of Ksswtytion, establshed d)ierts and Fth¥S ( Il dwrtiaL4e C￿pany. stsres in the cornpany re by The HFV Anal ca￿ in LIS4. The HPV al￿ Anal Cart8 F0uTrjat￿ board (C￿s1￿5 of f￿r [r￿mberS. The direc￿ are re$r#)￿'b￿ for the kgal, flnandali pr￿raM and rn￿ager￿t o¥wlght of ￿ tharlty. The Iwrd hdd hs ￿nL￿1 meeting on December 28, The dally respCfiSl￿1knes and mtssknn of tr Foundatkn are by the teams In the and ￿ UK. In the btter, the Dlrertor of irL OpttatioN4 ts re¥￿n¥t￿e the coorflnbtron ￿ thy.ttrday Vlhen tr Trusteu advertlse fty nthy b)3rd ffmbws, C¥KlhYates art 9￿￿¢•j the gwal wblL A dlverse mlx of ￿lIS and baCkgr￿TrY$ a￿ PrtyFertr¥e trL&ees are Intwmthved wor tt apOntsnenL As part ol t￿r inducbon, new trustees are an of the of The HFV mal Catxtr Foundaikni In addbtron to COF4e5 of the onJanlzatlon'5 flnandal dc￿rI￿nts, Waw aThJ PK4ldes. RI￿ Management The trustees of the Foundation hcld the reSF¢)ns¢￿1tty of safegu?￿l￿g the dwrws assets ar￿ are sa￿￿1ed that sterrfj are kn place to I￿￿9)te tIM)5e rbks ¥yNch thartty w f￿. Itls Inwrtant to note ￿t the parert and sjbthy orgWzatkns cptrate a5 crf enljty In athWThJ the mlssth of Ihe or9anisatlon. The rtvenue for the charity is dependent ¢k)natkns from tr put4￿. Income for the UK HFV ènd Anal CarTh Ftyjndailon In 2023 was £579,781 aThJ expeth4thre was £342,973. Total free re5erve5 at year affKJJnbJ to E281,655. Truees have the arnujnt ol re5erve5 it regaTds as a mlnlmum pntht wuirwnent. Tly have conduded that provision for three Lwernts"rvJ YeseNes that enable the wjanisation to meet ts finanoal commitsnerts induding grants, contracts aNS staff sakries is suffioenL Ths ￿1)Uld alkm time to manage cost re￿ctionS ty generate ftw)ds as reWI￿d whi￿¢ minimisirvj ￿ impact M service prtyi5￿. At 31 Decgnter 2023 tli5 amwnled lo £21,478. This indiotes a heathy swplus c+ free restrs of £260,177, whkh will be allo(ated for use In 2024 and 2025 to 5YPP(rt C￿r initiatives to anwM*r anal (Jrttr pthits, and Kcelerate pYevenlkJn and research methods that dimlnate human Pa￿lI)Ma￿￿jS, and ar¥91

RE RT EES 2023 Publlc Benefft The truees referred to the guklan￿ ¢￿taIn￿l in the (hwity cc￿55￿ 5 gufjdar￿ on put1￿ benefit when reweéding the chanvs alrrs atid obJettNes and in plam.ng ffijtu￿ a(livitie> Hlstory The Fwndation was fltst estsb114￿ in the USA In 2010 ty three slbllr4¥ who h)st thdr mother, aged 53, to 5ta9e IV HPV-related anal uFKer. Frvstrated by the tknpwtk arKI cL¥nmunty supt>t avallabk to ￿, they ueated the or9ani5atK)n lo fill the vold QLWY by scant w￿1(. soentific and medKal foajs on this disease and tt5 cause. human papbllomavlrus {HPV}. HPV owes anal Ca￿er aThJ at ast fNe cthw oKers, ar￿Un￿￿j to 5% of cancws worldwlde. T1￿ cancers prwentsble. In 2012, the or9￿1zAtion expgrKled to the UK wth 2013 as Its flr# fLII oPera￿onal year. Mltslon The HPV a￿1 Nnal C)rw FJJndatl)n em1￿ anal •TrJ accdwates preven￿Oft and resea methr)Js that ellmlrote anal caw and the ￿ruS that ouses tre cases, HPrf. HlghfKJht tre el human paplM(rnirus (HFV) kn contIa￿ ranw; Advor4te for prevenvon metros that wll and HPV.thted oncers, lThJuthng geThjer.￿Utr￿l vaccination.. e￿rnte a ￿re Ic the 5% cl al lthat are catsed bi HPV. wlth • on anal onw,. and The Ne•d A ThJndan￿ts1 obJe¢tyve of Foundatlons Is to retse the of anal carKer and 0￿r HPV.rekted can￿r$. HFV Is a cL4nmon 5kJn vlnjs that nearty every sexualty a¢iive perg)n will get at 5cffie point in thefjr lfve rpv affeils Èoth men and and is wit4e (ty 5% oftt wc4hJ's can￿r HPV causes of the anus. ceNx, Iwd and nrt perms, vagina, axl vtha. Protectlon against HFV through un￿1 HPV vac(Inati¢￿ is a CTltical putjlt health gcol. Wth HPV IdtrbtKled as a cause ofgx differenttypes ofcancer, a￿1 5% 01 cancer cases tyl¢tsid¢ rc ￿ kn￿rat￿ethat we wotecttheentire popuktion agalnst ￿. Tr eff￿t￿ to red￿e relatsd to HIW Is to wevent [nI￿al infection of the wrus through IrnmunLsatIc￿. The F￿jndatIc￿ atl￿e¥e$ thi5 impKrtant alm thwjh ts thrts to a(fvan￿ equal access to HPV otectKm for tJth W at¥1 glrls thrcwgh geThJeI-￿utraI vaconation agai￿t the ￿rus. At the Intrc¢Juthon d the v7ccirye in most ￿ntr￿ orty girls were abte to receve this lrfe.$a￿ry irtervention were generalty exclLJ8J. The crea￿1 [￿j the cc631ilknrs n the US UK to erwre all thIld￿n have equal auess to prot￿tion agalnst these eanc5. The US the rnIle￿ of re{￿n￿￿'r￿j HPV protect￿ to all thI￿re￿ in 2011. Follow￿ the FoundatK)n sffte-yearthcacy camFn In the sclKd4)asgJ HPV vaccinatKJn for iw began In SeErt￿ntser 2019. C￿r frKus ts the sa￿ wottttiin for a5 wel as girls auv55 Eurcyei and

023 ntin Whlle we work to prevent fubjre cases. it is also fvTrJornentsl that scierfjfic aThJ rnedical thsparTiies are addressed fc the populaiJn that will contlryje to be dwjncsed WTth HPV-reLed crn Ilke anal Canw. Treatment options have barely progressed 51rtt the 19705 aThJ minlmal researth has uThlertaken in new therdP￿s. The m￿￿31 and nt￿¢ communltb researth trds and mNest￿ in rThel leas to a cure. The stigma sur[￿rI1￿j •rnl oarKer rewo1￿ one of the centsBI d￿1￿5 to Improving ￿jt(Qrnes fv anal c3rKer patients. UnfC¥tUnJts￿, many medKal centres ￿de Ilmtted infmDon spedft to the ex¢erience ￿ anal cancer. Many patients feel isohitoj and Jack the supF#)rt arKI ebJoUc￿l resource5 that signifv3nUy improve quallty of lrfe durtng and after treatmenL Strategl•s to Achl•ve Our Go•L• We ath￿ve c￿r mIs￿L￿ kn the UK and US fhrwh collabcrfation ith scientits, dinwns, wr￿T$, oryan15jts.o￿, and government agendes,. e{lucatk￿ ￿ stskekJkJers and the general publK; survlvcf 51PPrt and Investment In the m&Jlcal and Saentir￿ community to eNJ HPV and the CaLW. SFedflcOl￿. we take aojon to destigmat nd ralse awareness attywt HPV, HPV.related cancws and anal C￿￿. lThyease acces5 to the vacdne; lrnprove xreenlng wotocols and care,. empov& anal can￿r thrlvejs: and xtelerate a cwe for anal can￿r aTrJ otrr HPV.relJted Illnes MOMAN Is •n l•l￿d. R•e• to End HPV The Nom￿ CaryakJn rnLse5 aware1￿ atoJt tre HPI.relèted cancer epwjemk In men and and educates atrp)Ut tJ)e impJrtarKe of ￿￿ersal HFV vxdnaYcA), challerrfJirvJ participants to theme endurance races auoss the worfd. It is thrwgh suth extreme of atNethJsm thot NOMEN h)nour the stru99le and Isolaoon that many ncer Pat￿nts led. N014AN has teen an hicredlbty s(Kcesslul ompahjn. SrKe its Ir¥3wJwal t￿rt In 2013 wlth the Barcelona - Iblza.. R¢)w to End HFW. ovw 200 Indi￿¢￿15 - arnl thelr hundrèts of gJPF¢rttss - have erftsxed the cause our vaknes. These NOMEN h)ve raised thwarw￿ ab¢xrt HP4 crn on a kxal, national intemational scak, as wdl as fvnds to sukyjrt our pr¢￿r￿me5. 2023 was a spedal year the I￿nda￿On as ts 10th annhErsary of the No￿ ornpa￿n. Bookndiry our event raleThJar, NOMAN rpders tr#Jk on the Haute R(￿ events at Crans-montsna and Ventwx. The Haute Route 15 the worfd'5 rTrJ5t pre51igious cydkn9 event fty amatwr cydists. Tr r&t5 unparallded experien￿ 3-,5.arKI 7. day professional road everts in the most kork qdlrbJ (lesritkitions wcffldwKbe. ￿rIr￿j the 3-day events, rlders tske on s<￿e 3C(lkni and KKJckn+ of ¥ErtOcal ascen( testir¥J I￿nselveS agaknst the most irfamous dlmbs In the wld. all In the name of wa￿1ng awareness of HPV-rektèJ Car￿5. Ald1t￿namVI at each tvent all p3rtldpants, {nearty 3000 parIkI￿nts In toial) are given ￿r END Htry socks to16ght LP the aThJ generate (onversaikjn atojt (￿r work to dSmlnate HPV ￿￿r5. ctrfwnder Trlstrn fvJm)da also spoke wr ml&sion to dlrninate HPV cancws at the wslage br￿.

July saw the ItAh anr4veYsary ethtKm of tr BarcelDna.IExza'. Rth¥ to ETrJ HFV, wr flagshlp event. NOMAN'S O￿n rowlng race pts teams of amatwr rowers agalA4 each other in a three-day wint mss the med￿eTronearn. Rowing across an o￿n Ls like no othw 5tort: it is as nxjth atout the crtsv5' atmlty to cope ￿￿ntalty as f( is ab￿rt techn￿Ue and physcal strength. The race has seen great interest amw adventwe seekws, and n)wers rarKJe freffl people wth p￿or expertence to ffl0￿ Seaso￿ rovts5 k¢knng to attwnrt an cKean row before commttvng to a knryer chalkn9e suth ¥$ the Padfk fx Adantk 2023 sèw great Interest from (￿r commlmlty, a￿1 the rrtum IA partlctsnts from lco￿ng to be part of thts speaal anniversary ra￿, akjngsde supwrters of OUT V•YJtk Thty Jolwj on water by Olympk gold medallsr, Will Satth MBE as our WX4AN afflba￿dCf wh)se partiapation 9EwabJ inueased Intsrest 8nd supwjrt for OLK cause. We are grntefvl for thè 9ew05ty of ￿ Trafyur3 Fourbjatkn fty 5UPP)rt of our campatqn and the FouTrdatkn's work In 2023 In the lonn of a mètching ContrI￿on of $150.000. We knk fcfft¥ard to ￿￿￿lIng on Inlttabs In tr cThivJ year& In 2018 and 2019 the FcNJndaYon wasinvolved In dIscuss￿5 to estsNtsh an a(kncy campahJn In Europe to 5ntrodu gender.rwtral vxonatth across the rewn )Id ccmp• eh'rrinate HPrfarelaW disease5. VMAN has partnered with the EuroFean can￿ OrwfrsallLN) (ECO} to athlpAe th15 mlsskn. ECO ¥¥ts￿5 trs red the burden of canw and irnprove wtcomes quallty of care for pthnts through mu￿d￿(lpl1rtary Inltktis. As the Eurcpean n￿40r"￿￿tt tsJpJaYon oryantsaticns woth'rvj In (aw, they convene oncc4ogv prOf￿￿)nal and patnts to a9ree cffl wky. for pc&bve d￿ngel and be the united voKe of the Euiopean can￿r communlty. Tojether wlth ECO. the FoundatOM k)oks forward to %4rrkJNJ ELwcwn PDW makef5 to eTrJ the sufferlr¥J caused by HPV can￿r$. In 2021. we achi￿ed a major Thltstor by seoJrlrKJ for the first b"me, a commttnnt to efimlnate HPV Can￿rS in EuroFes Beatlng CarKer Flan. The HPV Adjcffl Netsvcrt has built on this m)ior success With the folowing ach￿ In 2023, I￿lu￿n9 sUW>Orting Coun￿ that I￿ fallThJ behlTrJ. Publlcatlon of the 2r￿ •dltkn olth• HPV Polky Pr•v•nlkn Ad•$ On 22 June. 2023, the HFV Pr￿￿On Pc41q Atlas wa5 at the Rmrlan Parllam&L Thls latest upJate of the Atlas, In￿lalty published in 2020. led by the European Palllan￿tsry Fcrum for Sexual Ra)r0d￿tiVe ￿.ghts IEPF) scores 48 European gov￿Ments on thelr approxh to HFV Wev￿￿on - prfmary preventK)n {vaconab'on), condary prevention (screenlng), arnl Infrntp)n. The tojl akns at r￿￿d1Thj w>.trtrdate put4kly awdiL4ble informatron across am counlthes of VI￿} Eurcpean regle￿ In li￿ wth WHO ceTvKal cancer ellm1rwtw￿ strategy and ELTrrope's Pe3￿ng Canw Plan. The 2" eifrt)n hKJhlvJtrts the geoJrnphicJl disparltks whKh exlst in HFV PreVent￿n s acrc6s the WHO E￿Opean re9￿, as Ngh1l￿ted ty the ¥￿b* Ea5t-West thde In EPF'S so)res acr055 the continent.

The Atkis serv&s as a P￿￿1 to actkn.. undethrMrNJ t￿ wl for actjon to tse&Je HPV, in particiAar Ma pollcies related to HW immuNsatr)n, ceNcal SryEenw awJ onlire information, and urklerlines the knwrtance of IMplemen￿n9 the gcois c Europes Bthting Caw ikn. OLrt of 48 ￿ntr￿S in 9etJraphiol Ewq)e.' 39 countrles183%) offer a naUonal wwan¥ne. 30 courtrfes (64%) provlde gen(r-rutsal vx¢Jnation. 23 countrles149%1 malntaln an HPV Vacanat•￿ re9tsty. 25 cryjntrles (53%) e•sy40.fiThJ. g¢wtsrWnert.￿ted ￿lteS wtth gwj or exC&yw￿ irfomatton on HPV preventlon. Jn 2023, DenrnarK SweLn. Flnland, the IK, and Ireknj the tOP-pthfvJ courtries lft HPV preventyon. T natiorffj have Imr4en￿nted ￿-pr)c￿ Fdw, IndLKfing nauonal routine HPV program5 that are gender. ulral and fredy a￿dIlable, resulb.ry in hh vxdnakn rates yJppcted ty robu# Immunlsathjn data systems. Tl akn offer free HPV screenry for addt5 maithn wblic wthtes wtth thai, infomwkn by ties. Conversety. ctrJntrfes Ilke K0￿0 ￿ Ilerbaij￿ are at of the l&t, marked by a lèck of prfmary and Sec￿d￿Y preventl)n and an ab5erKe of rellaNe, thIe￿e-based infmtim prevenkn. The Atlas has been presented at severnl high.levd events through0￿ the ￿r Indi the Sert4an Parllament, ar In a presentstkm to senior polltloans aThl Fdkymakers In PoL3nd In Octob¥ 2023. Launch of HPV &l¢tlon Cro•tl• and Rominl• •nd support for HPV Co•Wtlon, Bulg•rtb In 2023, the HPV 5UPF¥Xtiry adNw ranv￿n5 on ellmlnatknn In Romanla, Croatki and B￿garIa to see rnre yoim9 ￿e0￿e Vaccinot￿ against HFV, in with the recThmmend)tlons of EurDpe's Beat￿9 Can￿r pfan, anrj ceThul sCr￿￿r￿j prcty¥ammes e&at41gled in eath cwnty. Eastem European tt￿rrtrI¢S fall behiTrJ rnany Ot￿ Eurcgean count￿5 In effThts to diminate HPV ¢arKers, w￿h low ￿1$ of HPV Immun&tb)n CWVKal s¢reenlng. E2th mMth, the HPV ktion nets¥tyk organlses video ccfifererw brtn9ir#J toJether physkiars, sdentists, put4ic ￿1th ekperts. and rePres￿￿t￿eS of mothers and your peop￿ from all over the respective countrs in or(lerto aL*lre5s ￿￿entify￿￿t￿irt￿ immment. In county Cwrdsnat￿s Ikive teen appointed In 2023 to SUPkhXt the Coalit￿ aThJ thtify a￿35 of need arn1 OPFX)rtunity. At ECO Surnn￿t in November 2023, wcfk In Romania, Buk)Jwla a￿1 CroalSa wa5 dbujssed at a we(l-attended satell rnetingi wludlng tsy the Ckwty Health Mith of Bul9aria. SFeilfic aththnents fvr each ofthe 2023 are dets[l￿ befvyrt.

NC MrrED 31 DECEMBER 2023 con Romanla HPV Acticffi Romanla- {A¢lUr￿ HPI Romanial ￿ WirvJ national organts)r& and to mobllse and J￿n forces to irnplement [MJIK￿5 at irKreasing HPV ￿￿C￿n3t￿ffi, s£reenlng and Infom)atlon ¢oveTrge. A wide range of Orga￿sat￿Ons have come tO9ether as wt of thls new ￿p3￿n, oll to aLtfjcn is ftt￿e￿ on three poirts,. Rcxbtine gender-neLthI HPV vac(inatKJn fty ap 11-1&￿r￿d$ with gJ% uptske by 2030. A nati£￿1 w>puLiti0n-￿th cemcal can￿r streeniw kyrwjrdmrne. based ￿ HPV te5Vng and includfjrrfj self. sampllng as an Ok)tKin fty hard-t￿each grtyJp5 and othw5. with 70% of women screerJ ty the age of 35 nd agaln ￿ age 45, to be by 2030. A SUStstr￿ pu￿￿ educ3thJn HPV awareness. vacdnatkn ènd s¢JeenlThJ. In 2023: In the context cl Wa￿￿ Carur Day (4th FeMwy) a det•te was padIan￿Ortan$ I￿$[n9 the theme Lrf 'Wc4nen's Ca￿er5 - DITectsirs ICK Improvirvj Pr&ntion. Early DS&Jnosts, )nd Earfy A￿55 to Tieatment to Reduce IrKlerKe aro Improve SuNfval Ratss., In order to Sdentfy publc kealth opp)rtunlttts to de(Te)se canw InddaKe Imwtye rats Immurisatlon and sueenlng )re key tcKAs In the PLblK heath tcdklt to &ldre55 IWJ In Mayi a ￿t￿lC awareness campaw was IwrKhed kn Rclnanian focthll sxadlums, reachlng thousaThJs of fans wlth our crlucal rnessage dar¥ps of HPV its link to at kasl diffwent types of caKer. objective of this campalgn 15 to Whten awarene55 and er￿j￿￿ge vacdnavon, in partkular through encouragirrfJ parents to wotect thT th'ldren by askJr#J thur <h)lors at(Jut the knmLmlsats)n. HPV Actton Romarkn was Lfficlalty laUrKI￿d, arrfl an inAh as dellvery and distrlbutlon, s well as combatiro wblbc mbuNlstJndiNJ arnl misinforniati￿. th15 cixnmlthEnt Is a 9gnificanl Step Croaya Intr¢<1uced GNV in 2016. immur¥salxm OYtrdge15 ¥￿1 bdow VIHO ellmknaiSon trrgets 0190%. In 2023.. Crothn pc4makers were In￿t￿j to an thrty ottc4>er the coalkn cl natthal SUPFKJrters of HPV prevention, hlghllghung the rnea￿ nat5onal aThJ Ictal ￿ganISa￿￿$ Can 9JPPOrt advocacy efforts to enC￿jrage uplake of vacclnatrffj In crfder to prevent HFV carws. 20 Octrt)tr, the group pawtiapate(I In the'stskeholder Forum "8etter H•alth for All: EU Glo￿1 He•lth Str4tegy', overviewing the upcoming pkns for the Coallkn and wesertlThJ the akns of the w￿C￿lI¥j can￿r SCTwlng Fwrams In Croova. Throughoui 2023. the coalft￿n was In ￿ter￿￿ on Noming Cmatia,, whith h)ve emphass8J the preventsbllty of HFV cancws throlth ImnwJnsaUon, aNI have highlpjhtej the underu￿11$￿tIon of HPV vacdne5 arr￿j wJurwJ pec, to a n)tb)r01 audvKe.

THE HPV AND ANAL NCER FOU DA HPV Artlon Croatya wa5 ¢)ffidaly launchgj on 6 Cecerniv at ￿ Croatkin padlament hosted ty Lvan Cdid MP. and rtualty vk YouTute. Brlnghg togthr exFvts frcffi epldemK4cJl#s, ￿lL7￿# PatJgrt5, gxiety groups the aim is to ueate a united appycoch to wnFove Pre￿ in HPV. Buloarla In Bul9ari), the HPV Attion pro￿tt anns at bn.rory togettr, unltlng and supp)rtTng cryanlsatths and Instltijtions that w￿k tthyards HPV ¥acanatlon and C￿¥￿al cancer sueening. Th65 campaign ￿11 be coc¥dinated wth Bulgarkin HW c0altty￿, a naomal expwt nM4Jovemmentsl coalltlon acrively supwrted by the World Heath Ownkauon. Ifs obJthe5 we.. Raising put4ic awareness aroJThJ the risk IA (￿bThJ tt vlrus,. Encouraging regular Sc￿nirlj,. Athieviry a hlgh I￿1 ol vacdnathjn. In &X(Kda￿e WHO recorn￿￿jatb￿S. In 2023: On 19 Septernber. 1epre5enktl￿ HPV Aclth Nthoth ￿bj?rian HFV coal￿10r¢ had a fruMul meets'rvJ in Sofia at the Bulgarfan ParfL4ment k(al MPS encoura￿d to c0ft￿nue efforts toward5 HPV prevention thr￿gh vaccination. Held M 10.12th No¥￿b￿, HPrf Actth metr￿rk reWe$￿tIVeS spoke at tr seccmd Buhjarkryn natlonal conference on vatt1ntrp￿￿Itrb1e diseasts, kir9e# thent e¥er In ccJnty dedkated to these toplts. orYn￿￿1 BuWrK4n HFV coalit￿ and Astra Fcyum FWThJ9t￿, speclalbt In vKclnatk)n TrJ preventyon con%tnel lo wojress aTrJ challryes wlthln BU￿art￿. Protert Europe The EU4Heatth pr(gr￿n￿ was adomed as a ye5p￿se to the COVID.19 PBTrJemK aThJ to reIr0￿ olsls kyepar&Jr￿SS In the EU. The paTraeM￿ highlig￿ the fragillty of nat)r¥31 heath syst￿nS. The EU4Health progromme wlll bdr contnbutlon to the w.term health chalberw ty budding 5trorw, rrKYe arKI mtye aCc￿￿ble health $y5￿S, thrcmjgh firwiclal support from the European Lhkn. Through thls lundlrrfji the PROTEcf-EiRCE woject wll dNimpk)n gvthr-rutrnl HPV vacclnatim In tr* EU to prote£t everyone aga1[￿ HPV wovkling infomwixjn arKI gu￿SarKe to EU meMtr￿ Strtes ￿. How profesYona15 better communkate dlredly 7hith young peth and thelr parents or raregfvers, How rre55agwNJ on can be tsIDw&Y to tkn retywte with yyjung pojple ￿ thelr parerts or caregivets. How other approa￿ ￿ as l￿ThI11r￿J var¥￿5 athknnt ￿lnes, coukl knprove HPV vacdne uptake. A key e￿n￿t c¢ the prOj￿t b ensJrfThJ that Lw5 os ￿11 glw15 are offered the vacdre. Gendw-neutr)l HPV vaconafjon Is one of the fi￿sh[P comnknents c¢ Europe's Beaung Car￿￿ Plan. Andir¥Js frcrfn thls project will contribute to the HPV AC￿C￿ ￿Ork as tr becnme avalatle.

E HPVAND AN Re5POnse to Europ8•n c￿nmI%1[0n call for •¥ld•nu on •ctk)n to v•¢rlnatkn •galnst cancw cau51n9 vlruses. The HPV ActJn supp)rted a re5￿p￿e to the ELW(wn ConwntsS￿ Call Evle￿e on canctr prevention - tion to promote vaUl￿n aga&￿t carw-caulffj vlwse5. The cfjnwttafjon irwited pU￿1C feedback on fijture inibabves to increase uptske of against ￿ Hepatitis B VINS Human WlkMnaviru& The ull fty evldentt ￿11 sUFVOrt the (kafarrfj of the European Ccrfnmission propcsal for J Council Recommendatk)n on vaccine?re￿tstAe cancers, vthich will te publis1￿d by of 2023. The HPV Action Ntho￿ emphased the ftAlowlng pdrts for IndusK>n In the Rec￿mendatI￿. l. tr achlmnent of HPV dknlnatm thrn￿h wder-nelrtrnl va¢£lnaUon. 2. 1r￿reaShg cobtrage of HBV vxdnavrm lTrllr4J kn new-t#xns. thklren tsk4Jr￿ps. 3. Ensuri￿ an inequalrts fcojs thrO￿9￿ut the recom￿￿. 4. ActNety trathrg monttodrvj kYC#3ress tth¥ards of HPV and HBV catKers elimination go81s. 5. Enhandng EU level &tts)n agalnst rnI￿nf(Thatic￿ arml d￿nf(￿Matkn vxdnath)n sockil rMe4a. 6. 9)pp￿ry J stable s(yply •)v6ronment for HFV aTh1 HBV vaccws acr(6s Eun)pe. 7. CreatÉng sYnerg￿S ttheen the EurcFean Commtssb)n the Wcrld Health Or9anization In [M￿ementI1 jlicies sirategies the diminaticfi of JI dise•ses caused ￿ HPV and HBV. 8. Urglng Mener Statss to adcrf public healthStrdte9￿Sthat kndude mukn'astskeholdtys eduoth)nal campalgns. 9. CUnm￿ln9 Member Siatesto ￿J￿fa￿1trte access to VacCha￿On aThJ ty ImrAement coydlnated vac£Snat#)n catch-up programmes Jmong tl ￿P￿ation. 10. SecurirYJ kjng-terni ccrfnmitment Eur¢ye•n Unim to the fUr￿lI¥j of ¥&dne•reVentab￿ ￿￿er5 research. Future plafts In 2024 and bey￿d, thè HPV kb'on Network wil: ComF4ete the PRoTE￿.EL￿OPE proJeLt and utllse Ihe (XW posgt4e for Atlbn Now. Continue to SUPFYt the national campahjns In B￿garIa, fJoatk arKI Romanla aThd acti￿lY cowder eyparn11ng the approach into Poland arn1 other cwntries whwe [￿L. Plold an AdvcKacy Symposlwn on 25 JarKory p￿1th a folhyhwp rrf￿rt. We wll learn the knons frorn the SYmp)￿uM for wcfk and erKowage othu5to utltsetheoutwts ￿ thr own campalgrks on HIV p)lty. RespoThJ to the fcthccffjlTrJ EC proposal ts an EU Coundl Re￿c￿Mendation on vacarE"preventatk cancers. Continue to dissemlnate and use 05 an a(fv(Kary the EPFIECO HPV Prevention PolKy Atlas. Use ECOS firne to Acceknte Manifesto and the Men and ca￿er RoMJmap to ralse HFV iSSLf5 during the European Partiarnent elettions. Continve to Paitipate In the M15sion P4)3rd on vacclnatlon chatrd by Pft)f Walter Rbdardl. Partlclpate in Intematic¥h4 HPV Awarerw Day and Eurwn Immunisatim Week.

HPV CO￿ltIOn UK In October 2022. the NOP+iAN Carry)BtsJn were proud to k4n for￿ Tfftlrth kJS Cthfjcal Cancw Trust to I3￿ch aTrJ co. thair the HPV CoaMIkn in Uniteil kn"ngthxn. Tr Coalrtton was officialy launthd in the Pae ol Westmlnster In an event hosted by stsndiro HPV &Jvttats, Jess ￿111￿$ MP. arxl supwted by rditlaans frorn both 9des of the a￿e. •$ as communty #aktholdtrs such as HFV carw ￿. The HPV Co&It1￿ i¢ •n exW grw of kodlng palknt grws, grwps, dIn￿an$, and exFert kndlv4duals who have come togettw to Inforni and U￿$ bJm towards elimlnatkn of HPV-reL4ted canttts- cancers atccwjnt foT 5% of all 12nc5 gk4)3ly. and wA)l¢h rthi. for the flrst time In h15tory. haNe the opFortunty to dlmtnate a5 a wbjlc health threat Despth the xale ofthe orwtuftty, the UK has trtt trj tske the step cldher countrks, suth as Australia aNI Canada, In develcplrKJ an plan for cervkal carKer eliminatkn. The UK a150 ljgs bthlTrJ ￿ Ewopean Unbn %%thlch, through the Beatiro Can￿r Plan, has sw? fvrt￿r, In commltting to dknlnate all HPV CaT￿r9. The H C031it1on Is the￿fore eager to see the UK F¥Jt in pL4¢e a ¢￿￿rete pkn ftr elninthn as a matter of wlorty, target&1 at the while rawe of HFV-related On￿￿$ ￿p￿tir￿j access to pTeventstJve interverticfis for all parts of the The Coalllhjn wlll sI￿d at the luefront LK rK4makJrwJ and vlll Mng together J memt•thlp of pat￿rt oryanlsaljons, pro1￿Onal groups. dirwcians. and eywt indNhJuals to aTrJ denKJnstrate broad staktholder c(Jr6ensus artsjnd the Sign￿(anI - and as yet unharnessed - C9F￿rtunity to pur9Je elimination in the UK. The membershlp wlll for commthent and actth from Il IX govemments to wrsue elirninabon of the whcle range crf HpV.￿ated cancers, in LKth aThl women. Publkatlon of th•'Ro•dm•p tow•rd• m•klng the eMmln•tlon of •ll HPV-r•l•t•d • r••llty acro the UK. In May 2023. t￿ Coalttjon publlsw a Roa(knap iowarfts makkng tr ellmlna￿on of all HPVYelated cal￿er5 a reality t<rcw the UK. Thls sets out amtrxbous, yet reall￿]¢ wts, mawrKJ OLrt kty areas of Jthon. IrKludlng milestones, The Roadrnèp seThts ès a to Govemments across the r￿Jr naticrs of the UK to tske athon, Whi￿ provldlng the blueprint of hjw ellmlnatton can be de1￿￿Ted. Tr goal Is slm'. Make the dlmlrofjon of all HPV.relJted Can￿r$ reallty across the LIK. We have many of the tooLs avalable to us now to n7ake a realty, and we must ensure it15 grasped wlthout dday. To achleve th15, we must ensure fMdatkNs of HPV prevenkn are strtyhened. The Ro)dmap Ls th￿trOre made up of a numbw of buAdlrvJ blc¥s- vlth a$s(￿ated acth)ns- that to elminatim.. l. Nltional and regRY￿1 le&der&lip ar#1 acC￿ntabl1ty 2. Improvin9 alucatknn on HW to tackle stlgma drive acLW to prewentk 3. Maklng sure everyo￿ has equftable acress to sueening aThJ earty dIa9￿615 4. Restorfng and bcost1￿ Immunisatk)n Uk*ake. Ind￿kng (atth.up proJrammes 5. Enhandro the dats, digital aThJ workfrKtt infr&4n 6. Embradtyj fu￿re innovatN￿s io

It ts CTltkèl that UK govnrw)ts set a oyKrete strnte9y ftr tre arnlnatkn (rf al HPrf.rel)t&1 Ca￿0J5, hldenkng the scope ofour amt4tion orKer elhninatkn. ow felkxv memb&s ofthe HPV CoaFJdon. we and te to gJPFQrt the of TKomrwxlaIk￿ aTra tr meDrwJfiA * to &YV4ert PW/.reLed Urm s p￿ICatIC￿ tr Ro•thnap nolkxba ur4voge at I￿rKh, an.OpEd autfrfftd ty the Foundatkn's CEO Davld Wlntefft¢d kn The Ttrne& it hos akn ￿atIed ￿ G)ally¢￿ to engage psky ar¥Y rfamentary stak&dders to faclht&e whjer arothi1 ts rnadffl￿ ar1 ulbmate goal Lrf ellmlrotkn. Th1$ Includul a Weknwn#er Hall HPV vKtsnatlon •ttathJ by MPS a￿1 nir4s wth UK Health Seojrlty Agery (UKHS4) the gKwtrnmert rÈswth for E￿￿￿.WIde pubk hèath pr(rttttlon Inlecdous dlase capèblllty, NHS Englar#J, an to IO Street kn brfdtre Mlnffith He1 In November 2023, NHS thld execl￿￿E F¥ft¢hard pd to eKffthate Ca￿ ty 2040. J key step kn the fr)urrw tr) the dnWnaUon of al HFV oncers. In De¢en•, NHS EThJWs first Vacdnalkn Strrte9Y Was publlshed c￿(nIr￿J J f(xu C￿ knytr¥lrwJ HPV vxdnth cow rntss. In 2024, ￿ Coallth)n erwge NHS Ewd x a partner In the ￿p￿m￿t￿lICI) of the ewftknkn ambilkn, to e￿re that HFV at the tcy of ts wKl• be a dwrge ( wemment. We WAII work wth local syst￿￿ to knyove HPV and to fty commItrn￿ dlmin4W¢m In the de#thed nath)r6. Lthdlw th• dmrge for global gmdtr-n•uhl MPV ¥•(ln•tlon In 2023, a record nunknr (rfctyjths aLW iws th vxdn•UM pr(¥•￿, 4lor45th glrfs. But gendtr. nejtral HPV Imrnuthtk￿ wwammes, to cancets. Jre ￿11 Cffb ullsed In ￿ rrfmrjty of prowanms 9￿ba￿. Ifthis year Ls to 90 by, It be rase for kng. In the pa# star we hast seen IrKs635ed Va¢d￿ 94Wles avaUalAe. nE+V sbJ¢k$ 1I9hllghtJng the effeLtthwÈss ol wKler.neutrnl ImM￿lsatIon, kntJeasoJ Cal￿ for I￿(￿1)n ry* vacrkne gwKler•ality 9rourbts, tr OPPthinSty to spwj up progress of cerviLal ancer, aThl In tum 411 HPV Car￿ Yet tth SUII 5srrk to be dfft. N(N4N c(x)Unues tv lead global effryts for Ihe iTrJusb)n of boys brto (￿ntrIes, HPV ImmunLs&tion prografflmes. In 2023. wefrd the Global Hprf Consortjwn's laur￿th In Kual) Lumwr to s(we the fra￿e￿OI to t glob41 on onc￿, sp(e at a p)rl drsasskn kn W2ium.' Ellminail)n of HPV QrThs: Cyeam or Rthfty7 {RE￿rrY11, In aldjtkn to Gc4)al on m￿.5 ￿1th IGWH), as dLKu5d tekny. In 2023 W￿ annwrKed o new ￿rtne1th￿l KX4IWI 1slvKI.. Rxe to ErKf HPVGThnpaiw aTrJ 13obal ILlfon on Men's Health (Glmll, ￿ c#yanlsatk¥) dedL&l io health and hou-belrg on a knl ￿ale. Tc*ethex we are embarfvthn9 a m15sh)n to ffwJre knl Unl￿01 actss to Htty vac(inath)n, a vtsl li

FOR THE YEAR ENDED 31 DECEMBER Why 15 thi5 pathty5hip (nKial? HpV￿￿ted disease5 affert nMllon5 wryklide. wresFth of ￿. HFV can cause • range of t4￿r5 . cer¥iol, anJl. pende. win4. vufvar, lwd and nxk - as weu as g￿1￿31 warts and recurrent rewratory pa￿llOmato5￿ (RRPI. Yet gender-neutsal HPV ￿￿(Inat￿)n. dryite now Leing a Ylagthlp, carttr prevention Follty In the EUro￿n Unlon las detslled In Eurwets Beatkng Han, 20211, ts stdl cfflly the gdd stsndard of otects.on in a minority c( HPV vKanation projrnmrnes. In most Count￿ wfth an Htry vactifi￿n wogramme, only girfs vaconated. Gender.neUt￿ vaconatr.on remairts a controv￿1 e5teoalty for lower4ncome countrles w￿h very hlgh ratesofceNkal rarttr, arKI ts not yrtfvlty r￿fy￿r￿ded bytr Healih OfwuSat￿n or 9JPWrted by GAVI. By loa&r4 onty on the of girfs to (en￿1 rarKer. glrts￿ty prc4Jrnrnme5 fail to wotert males sufficientty from the cancers cw5ed by HPV. They also fail to proted urwacanated women from infXlon by men. a particular problem ffi countries with vK(ination rnte5 in girfs. Girtsd ￿th anal cmr anNIal￿. Anal can￿r Inciden￿ Is IncreaslrKJ aTrJ afferts rrKrfe p8)F4e across ewy year. The 9xlal s￿9Ma that anal rarKer carrfes preverts fair aTrJ eqLltsbbe corNusali)n, awareness, and t￿￿n9 to sLFpl￿ researth *)d carè for people wrth the dlsea5e. 12

EHPV E TRusfE Supptrt and Infor￿￿tkn Ls limlted anal caw thri4w ltyjr fDT wrvivors) many thrivers Mer meet another anal cancer F4tient. The yovldos forvms arJ a peer m￿tOr1￿j program to support thrlvers to dose this gap. The Peer to Peer SLVWt PrryJram 6 a free seryKe Fowded by the F￿Jndati0n in the UK nd USA to connect pthnts caregl¥ers fa¢irrfJ the thals Lyowjht on by anal wlth a peer who has urertaken the S￿￿e joumey. Conrths a￿ avallable for an￿ne at any stwje fnMI rthyty di491￿ed to years after trethent. Vdunteer5 Ilsten and help thrfvers Uwough thelr (arKef j￿ ty sha￿n9 their own on treatmenL stSgma a￿1 soclal experiences relatin9 to an onal cancer dvagnosos. The pr(wn￿'S 9oals we to irnp￿ the lives of those affeLted by anal cancer and glve a Yo￿e and a ctffimu1￿. Tr program aLw rnatd￿ orE9lvers tcgether. At the of 2023, the HPVACVS Peer lo Peer Swrt Prcornm o￿lUd￿l 1199 thrlvus, carek¥vets. and pew mentors. Our onllne eduCa￿c￿al events contlnue to provkle and rexJurce5 fw thrivvs. Ta￿ng Care of YLXJ.. PJlanaglng Slde Effects from Treatrnent For Anal Cancerf featuring exw dinKlans whotreat peoF4e liwng anal cancer as wel as a panel of t￿1verS ha5 teen by over S.9￿ the end of 2023. 'Liwng and Thrillng ther Treatment for can￿r. Wressong Lw Tem Skle Effertg. was 11,OCKI til￿ ty the ernl of the year. An•1 Can￿r P•llent on ￿tCknr 21sr 2023. the Anal Canctr F￿r￿1￿￿ the s￿)rn1 Anal Cancer Pattt SunmlL Medlcal professknnaLs 5Foke ab￿rt cartt cwses, tre41m￿, and h(M to mldgate the varhws $￿e effects of thLYnoradlation. We also heard from othrotes th taLght us, through sharfng thelr own rtortes, to use our personal exper￿n￿ to advaKe the fight a9aknst ènal carTh. Flndty. thrsvers We￿ abk to netwck b¢th in groups and wlthln one-￿￿￿ sts510r￿ whlch. fDr w pe￿, was tt tyme ￿Y weo meedrvJ a thrlver. The conference was ueated to kvovide an annual cppryiuth for anal carw patnts aTrJ care9lvers to learn Irorn medic41 profe55WiaLs. conrrt with experts and eath othtt, aNI lake ac￿￿ to empo¥er th&n5elves thts communty. Over 449 peoF4e reg&efEd lor the from 22 ctyJntrs tyJnd tt W(￿d. Anal Cancer F￿v￿lat￿ CtrFounder Jus￿r￿ Ajmada f&irth￿ the dtys events. EX￿rtS induding Kevln Du, Caihy Eng, and Pavl ROn￿ser SF4)ke at¥)ut anal ¢auw. treatmerts. emerglng ￿r￿es, aTrJ qualty of Ilfe after treatment. Thrlvers bvere glven the CYp￿tunIty to ask qwtions Ilve. as hEII as to connect with one aTr)ther. We 45wld Ilke tts make gjre every faciw ha5 rn to the sarr irfLYrnatlon as thelr d(Ktors. RecJ)rding5 of the davs events are avalat4e on YouTube •￿1 hos 1S(M) ￿e+¥s ￿nce thwr publicath)n. 13

THE HPVAND AN TRU Int¢rn•tkn•l Anal Ne0pth￿ Socl•ty (IANS) IANS, the Internticrnl Anal WL75va Sc￿￿ty, creates gul(1dl￿ aThY ￿[s￿rts reSea￿h essential to i)reveniirKJ arKI treatirs orTh. JANS was ovted wAth a seed grant from the FouTrJatM. IAMS m1ssc￿Is to a forum fc wAth a broad of backwurvj, vlthvonts and gec¥Jraphlc ot1gln, an exchange of Ideas atvj th￿￿nat￿)n of re9ardiThJ the pathcgewls. diagnos15, treatment •nd preventkn rf anal neoF4. In gJPFt dthls ms4on IANS: Cevew positKm P3pus regbr(&ng the trtsitment preventkffi (A anal rwIaS￿. ReFfesents the oF4nlon cl IANS regar(ling the tOPiC5 to other professlonal publlc organlzatlons, reguktory aut￿)N￿ aThJ 9ovemmentsi Ly)die5. Encourages the devdopment ol a robust research agthda on the pathogvsls, d￿9n￿5, treatrnent and evention of anal wfAasla. Develops educatl(Ywl materlals and tralnlThJ courses Ihat e￿rage the enty of a broad SFéctrum of clinloans into the r￿d of anal neopla, arml that furttvs and depth of skllls of clinicians needed to optlmalfy dIagr￿. treat and we¥￿t anal na. rvdco eduothjnal materials for patierts tmth a￿1 rcylJsw. Inforni•tlon and C4￿￿•cO0￿ The Foundatlon's Jnol ycgrdm vrtbyte leaturts a of resowcts ￿ Is J ￿Tte of inforrnatlon. supF<rt and In¥ratkn fc iknts and lamilies affected ty anal ar￿. r focus Is erfjurlng pailents get the Infwmation aThJ Supp￿ they nd durTrrKJ their anal carKer Journey. Our LI￿n9 AnaIcar￿rsecoon featsjres Infwnatkn for patlentsatall sbjes oftl)e anal caKvJoLwfrom newtydlagtwd to post.treatment resources. s￿h as ￿)W physcal therapy C￿ help with anal carTh treatsnent recovery. The site ' the mo# ccynwehenlve source of informatlon Yde effeLts the effttt mlljgation durtng and after anal cancer treatment, This digital fvJb $ kwlèted with pergjnal thriver slories (FetnIs.sto￿ oftheir experiences), infomwtion at>wt helpful medtal rttources, aTrJ kyofesgonal medkal L¥)ds. as wdl as Connecd￿ to other patlents and ¢are9ivws throusth our Peer to Peer ￿pport Pr(rfJram. r goal In 2023 con1kn￿ to be e￿rIng that mtye tmvers hm actess to the Inftymat1￿ they rwd to face they carTh ioumey through tal￿ts1 ￿￿reath based u) wr suppxier base )nd o ne￿￿etter ser￿S for patlents and Care9￿S, fOC￿e￿ cffi ¢wr exret aThJ Fowlar reswrces. ccffjrThJnications trdtegy contlnues to focu5 on conslwcy and provkliro-uselul" infmtion. contentCo￿n9 treatmert and r￿rch UF*Jate5, strles from cc¥nmunlty members, a￿1 explairws of￿1 servlces and hcw we suppxt the anbl communty. 14

THE HPV AND ANAL ER NDATI THE YEAR ENDED IDE EMBER 2 ACF'5 2023 di￿ impxt indLKks: 185 new and carKer thrivus and rJregNUS 9griThJ LV to be matow thr¢y4h the Peer-to.Peer Supwt gram. 330 anal ￿n￿r caregws Wped by tr I:1 Patr￿t Navwtion knice. Peer to Peer &Jp signups in 2023 are up 49% on 2020 frju￿$. 7 thriwers sharing their story publicty with our community Share Your Story Inltlau 650+ Pecy￿ partldpattng In wr infomkibonal frxurrs. lknrall, In 2023. ACF dlrectty ser¥d over 1,10) anal Ca￿er pa* our best.i)3ce. Wlih the EU BeatlrKJ CarKv Flan Specifical￿ IrLludlng rtiors on HPV o￿tr$ within ts remi( we have a mandateto 9oin 5UPF#Yt and ernp)wer staketK4ders within member states t¢ eliminate HPV With 410% of carKers in region preVentsb￿, the exten4on of HPV vxcinakn.on prcgrdmme5 to pro￿ Lw5 a5 Y￿1 as gir15 pfovKJes a recwifed and effertive rnear￿ to tsC￿e canty. By contSnuing to build our ewdeno base, seekiffj and identiNrvJ barr￿ to uptake In EC member countrles, harrEssSng the possibllttles pre￿d by Eurcpe's BeatiThJ Flan and laumlirKJ akncacy groups in memter thtes, we are confldent that r￿re countries W￿11 agn up to neutral pri￿￿0￿ In1tJa￿￿. A(￿rtIo￿lIV, y￿ will ￿lId on these natk)Dal aTrJ regional er￿eaVoUrs, by tskiro our campaign gbbal in 2024, workj.ng aobal Actiorn on Men's Health will develop an evidenctrbased case for gh)bal ￿d￿-nwtTal HPV vacanatsn, and Jts'li5ing hpjh.kvel symposlurn6 s￿h as Worfd Hearth Assembty and theW￿ld can￿ c￿Te$S to rec(#Jnkn. ark1 an knternauonal allkince for gender.neutral HPV vacdnatth. 15

HP li Thrw the Pa)14AA 5$ an I￿a￿l Campalgn, collatrirationsth afvocates aTh1 legislator5, rnedla attention ar￿ athletic event pa￿(￿PatIon, a broader L% Unders￿r￿rWj the of prO￿1v4 all thlldren agwnst HPV. Wlth the NOMAN sde oftr ￿ganIS￿)n aJirwJ ￿ Hpvthrek￿ actpiits. ow platsm is grcwing frcfft which to tYoatha5t Lwr message. We wll contlnue to wsh legi4atfve, research a￿1 F4)Iy ¢JwryJes to end anbl carw and Imkyove the lfves of those affected by IL We are e¥ated ty the rewse to wr Pat)t Sunyrmt ￿d"Ask the sessions and 6ook foNard to provhling more touthwrts for ￿Jr ccffimunoty In 2024. Ow Peer-ttrPeer support tyogram retsln5 Its ImFQrtan In sUPPOrtirv4 and anal can￿r survwrys and ¢aregfva% Uiilizlrvj digrtal pL4tforms, we will reach a wlder proportbn c the anal car£tr comrnunwy, ￿￿11￿j pattents to galn wNers tD the corKwns have Jnd to cenn￿t to other anol c3rKer patrt e%￿er￿s. We th￿k all of ojr doThys and hx>k lo￿ard to crtknimng missKffl to unpowtranal cancer patients accelerate PreVen￿On and researth rDetWs that ellmlnats anal car￿1 and the vlrus that Ca￿e$ the mafvrity of cases. HPV. 16

The tn￿eeS (WIKJ are akn the dffttols crf Tt HPI •J Aro1 Car(tr Founthkn Lknked) for tr wrposes clojmpany lawl ore resrons4e wepathg the Re￿t0ftheTru￿lTrl the fina￿]￿ statemwts in acrordarKe wlth appltable law and Un￿1 AcC(Art￿j star￿ords ILWted (kna1￿ Acceptsj Pawntlng Pradice), i￿lUdI￿J nandal Rep￿9 Stsndard 102 Tr FWn0￿ RwbThJ str￿ op￿katIe In lfv UK ar¥J Rq)utrAic of Ir￿1, CoMp￿Y law the tr￿tee5 trj wepwe fv•rthl ststements fty e1 flnandal y￿r tNN¢h gl¥t a true and falr of the stste of affairs of the charltable arY of ￿ irKtynlr#J resouTce5 a￿1 apr4scatK￿ of Ind￿lIng the knKcrfne and ex￿n(￿t￿re, ￿ the thgrrtth c(Mmp8ny tr th)t PtrKKI. In txgp8rlNJ th(se flnand staterneits, the tsu5tee5 are rewlred to sefert sultst4e •c¢0￿￿n9 aThl appty them (￿￿erth Ihe meihc#ts and princi￿ in the SORP make I￿JgeM￿￿ and estlmates that a￿ re¥thit4e pr￿ epare ￿ flnanda ststtrnerts gokng corKem ba￿$ unkss * Is InaFwrfa to E5ume that the dwrttatle cornpary wll contknue In txtslness. the finarKI)I pc6itOon of the tharftable Cr￿panY and to enle them to ertsure that finandal staterrents comply wlth the cCfflpB￿ 2006. TW are akn resW￿t￿e for gfegwrdlThJ the assets of the chathble compbny 4rJ I In 9> tsr 45 the truts are aware.. therels rw) relevant knlormatkn clYAlch the dwrftst4e £ty￿an¥s eDmWs are unaware; arKI trustees have taken all steF6 t￿3t thry ought to tsken to rThike themsel￿ awa￿ of The IndeFthlent t¥amlMr, CJoryw LLP, be prpoxl for rt4Fnlmert ot f(xltrth))mhYJ Annuol GenuJl MeeVr¥J, rwt has betn Nepara1 kn actrydJKe lth the ¥￿la1 Part 15 (rf Act 2Crf)6 rejatlrvj to APPROVAL Thls reFQrt was by Board d tXrectors ar￿ Tru#ees on ￿ Sknnlr 2024 ned thdr behair 17

I ￿port to the dwty tr￿ on my t¥￿￿￿nati￿ d the Kcwnts d the c￿anY ￿ the yw end&J 31 December 2023. Rejponsibilltieg •nd btisis ol report % the trustees Of￿ charits14e compony (and akn ts d¥ettor5 the purF￿SeS cl ccrfnpany law) you we respo1￿￿￿e the preparation of the ac£ounts in ac(Crfdan￿ ￿￿th the requirements of the Companles Act 2006 {he 2006 kt?. Y￿j are 5aYsffed that accwnts of the Company are Tr)t requlrwj by (harlty or o)mpany law to be audrted and Havlw satlsned mysdf that fv amnts cl the c￿nY are ￿t requir& to be a￿J￿e￿ under Part 16 of the 2006 Pct and •re in(kputhnt eYan4natK￿, I rewt In rewt rA my examlnab"¢t) of Companys accounts carTied out under se(O'on 145 of the (￿antIeS Art 2011 Cthe 2011 ALf. In Ca￿￿g out myevjminabon I hJ folkn¥ed the Dlrectkjns glven by the ￿aTrty CthnrNssMJn ￿jer seLknn 14515Xbl of the 2011 I<t. Independent éxamlnerfs statement SIn￿ the Company's gross Income exceeds £250.(￿ eyariner rn￿5t be a member of a Ilsted kn sethon 145 of the 2011 AtL I ￿firrn that l am qU￿lfd to u￿ertake ￿ ebzmiMt5on becutse l am a re9lstered member of ICAEW which is of the listed Lvjles. I hove corn￿eted my exanMrwtKJn. I confinn that rK fflatter5 come to my atteniith In ccfirrton ￿th the examlnafjcffj glrrtJ rne to bekne that in any matsrfal res￿￿. l. accountlrKJ records not kept as requlred ty seLtiM 386 of ￿ 2006 ALt; 2. the accounts do Trjt accord wth those rectyts,. or 3. the accounts drj Tr)t crynF4y 7Atth the accountlng wUtren￿ts d sttuon 396 of the 2CX)6 Art cther than any reouliennt that the accounts a Irue and law w+tith is not a rkwtter ¢))n￿dered Js pjrt of )n Independent ejaminèlion; LY 4. the accou)ts have not txen weweil ￿ rKcorthnce ith the methLth aThJ prirripks of the kntement Recommended prdth￿ for a￿Ount1￿j aThJ rewtlng ty charities a[￿kab￿ to d)arltle5 preparlng th*r Jccrwjnts In accordan￿ the Finanoal Rrfkni'w Stsndard aOicable in the UK and Republk of Irekind (FPS 102). I have no concems and have come •yoss no ckner rnatte￿ In connethon vhth the eyanwna￿0n to wNch artth￿c shwkl be diawn In thls reptrt kn tyder ro Wbabk a woper uwwkrskThllrrfJ of the ￿£￿nts to be read￿d. Rithard B￿lIr￿jhur$t Knox Cropper LLP Chartere(l Accountants 65.68 Leadenhal Stree( L￿n, EC3A 2AD 2610912024 18

THE COME 2023 Total Funds 2022 Total Funds Funds Funds INCOME AND ENDOWMEIITS FROM DOna￿on5 and Legades 122.220 122.220 90,094 0￿r TradiryJ ActiM￿e$ Invtstmert Income 457,311 457,311 2x1 64,776 Tatsl EXPENDITURE ON Ratslng ThJnd5 95,515 95.515 16,407 CHARITABLE AcnviTZES Care and Support Awareness Ralslng & Research for a Cure 47.757 192,337 7,361 47,757 192.337 47,957 103,849 4,796 TOTAL 973 NEY INCOMEI(EXPENDrnJRE) 236,808 236008 118,117) RECONCILIATI(bN OF FUNDS Totsl Amds BrrAKJht Forword 44,847 13,100 57.947 TOTAL FUNDS CARRIED FORWARD £281655 £294 755 19

2023 2022 FIXED AssffS 12 CURREpif ASSErs Debtors sh It B)nk ird In tr4rKI 13 1.791 831 DITORS: Amounts f•lllng wlthln on• y••r J4 (8,9WJI (10,663) MEf CllRREiif ASSErs LIABILrnES 57,947 Nrr ASSETS É57 947 FUNDS Lknrestrlrted Fw Restrlcted Funds 16 281.655 13,100 44,847 13.100 TOTAL FUNDS The dwltsble Col￿nY L4 enll¥ed b) fmm urAler S•lb)n 477 of im Art 2006 for the year ended 31 t>ecwrthr 2023. The members the ccAnpJny ty ot￿n of Its fknarKI)I statwrts for the yw ￿ded 31 Oecember 2023 In accorda￿ wth SeLkn 476 clthe P£t 200& The trustees xkncw thdr res(￿s￿lt￿S for lo) er6urlrrtJ that tPt tharlable clyroany keeps accMrthKI re£fmts that coriyPy ￿ Sedlcr6 386 and 387 of the Companies Act 21)J6 and (b) Preparlng flnanaal statements whKh gi￿ a true arml faSr ¥￿¥ of the state of the thadtabSe crynpany as * the erKI of exh finaTrl y&ir of Ws defhyt for eath Ibnandal y In accordarte wlth the requirements of Sertknrn% 394 and 395 a￿1 whkh Otherw1￿ Clxn￿Y wlth the requements ofthE COrnpan￿ 20CA rel¥kn to statemerts. ￿ far as applcable to tr d￿rttab￿ ccIn￿nY. subjert to the small reglme. The fin￿da1 statemerts apprnbYJJ ty the 8oanl CA Trusites and *th)rI￿ for 28 ¥anber 2024 and ￿tTe sha￿d on Rs behay ty: T Akhada- Trustee

E HPV AND AN 2023 2022 Net incomel{e¥w)(fitU￿> for the reixytry DepreC￿tIOn charge Interest payable Investrnent irKome (Increaselldeuease kn debtows InCrea￿(de￿eosel h crei1th5 {18,lJ7) 1250) (960) (1,683) (22) (504) 2,594 Net cash p￿ded byl(LwI in) operaVn9 INVESTING Acri￿ Investment Incc*ne Purchase of equlpment Net cash provloed byllused kn) SnI￿tir9 xtithies FINANc￿G Acnvmes Repayrnent of t¥Jrrowlr Cash Inflow5 Irc￿ new Cth flows from flnbndrrfj a¢lvlt6es 233,915 16,019 29) 22 Change In cuh and cash e4ulv•knts In th• r¢ptsrtSng perfod Cash •thd cash •qulv•knts •t the b•9innlng of th• reportlng perlod Cash and ¢ash equlv•l•nts at th• qnd of th• 234,165 (16.027) 67,779 83,806 301,944 67,779 21

ACCOUNTING pouaES Basls of Pr•parntlon of Acwirts The flroncial statements of the charitable compwry. tiich Is a public ￿nefft entty wder FRS 101 have be preparej in accordan￿ wrth the thartues SORP (FRS 1021 Accountyng arn1 Remiw ty Charibes: Statement of Recommended prnCti￿ applicable to tharities pr￿rir￿ th￿r acajunts in aCCCfdar￿e wth ￿ ￿nantial Reporting Standard aprAlcabk In the UK and Reput4ic of IrekTrJ IFRS 1021, FinarKial Rwt"n9 Stsndard 102'The Nnantial RepoTbn9 Stsndard apFIKable In ￿ UK Rewblic d Ird' and tr cryan￿$ kt 20C6. fin0￿￿1 statements have teen prepared ￿ the hlsiorlcal tost tonvèntsn. Golng Concern trustees ¢ongd¥ tl4it thwe we urKortalnlJe5 aixThrt the Charws ablllty tts ¢(￿￿nue as a Wrij Fln•Klal R•portlng Sl•nd•nl 102- rnthK•d dlsdosure exemptlons The thariVJble company has taken advantrge ol the following disdosure exemptbjis in pryring these Flnanclal ststen￿nts, as Fennltte(J by FRS 102 The Fkw¥JJl Wrtlr#J StJndaTd applicab￿ In the UK aTr Rewbfic of Iretsnd,, • The rejLIrer￿ of Se¢tlM 7 aierrrt Gl Htrrts. Income All Income Ls re￿￿n￿ed In ￿ &atement of P•Mes orKe the thèrbty has enOt5wnw to fiJnds, It Is prcJbte that tr I￿orne wlli be recdved am￿nt can be meawred rtllabty. Exp•ndltur• LIabIl￿$ are recognw ès eKpwthtwe as as the￿ 15 a l of constructive obllgatlon o)mmltUng the dwrity to that exFenditure, it is probable t￿at a transfer of eCo￿rt tenefits wlll be required in setdement aN the amojnt of the c+JlwJation can be measured rdhibty. Expendrture is afxounted ts on an awuaLs Iwgs and been dasslfied under headlngs that a99re9tte al cc6t relatsj to the otegory. Where cannot be dSr&y a￿￿rted to partular headiNJs they been al￿ated to actNilie5 on a basls cor&stent with the u of resour￿. Grants ¢)ffered 9￿lect to cor￿n￿)n$ bthtch rYJt been met èt the year end date are rKJted as a commltment but not accru8J as eXpend￿u￿. Tangltsl• Flx•d Asmts Deye¢KItKJn is provKled at the fi4bwng annual rs to vfflte Lrff eath asset over its estimated usefvl Ctean Ixat acce5%rn- 3 year& T•xatlon The chanty is ￿eMpt frcffi typorntion tsx dWrItab￿ acbvibe& Fund Accounll Unreslrlrted fuThts can be used In xc(ttlw wlh tts ttwltsble ¢OJ￿￿¥eS at the dxreuon ofthe trustee5. Restrictgj fijnds can only be used for partialar rethLted purrthe within tl Ltycts of the chw*y. Re￿rf¢tKIrS

THEA AccouNfThG pouaES- ¢ontlnu•d nd Aecountl Further wlJnaWon of the nature aTh1 of th fu￿ is Ind￿ In the rKtss to the finanthl ststements. The charrtat4e c(Ynpany Lwates a defmed contn.txrt￿n per￿n Contrkni rtlon5 payabfe to the tharltaUe company's per&Kn scheme are tharged to ￿ strt￿n of F￿al￿al Actiwdes In the rFod to whkh they rdatr. Judgements and K•y of Estlmatlon Uncert•lnty. No judgen￿t (apart those invLYwng estirnaiesl have been In tre proces5 of apF4wry the ab)ve accountthvJ OKie5 that hove sJth13nt dfert on amunts re(0gTh￿ in finarKlal Statem￿1. GRApifs ANO DONATIONS 2023 2022 Grants DonatkJn5 aryl glft akl lo,(￿) 112,220 122 220 85,156 OThER TKAND114G ACIIVITIES 2023 2022 FLndratslrrfJ Ew)ts 457 311 RA151NG FUNDS Ratslng Domtlons •nd Leg•d 2023 2022 Stsff Costs D•ent Expenses t)onor Software Subscrlpuon Event ExFenses 5uppc*t Costs 6,58S 42 2,167 4,626 32 3,246 &3,139 2,108 23

E YEAR EN CHARrrABLE ACTMTIES cosrs Grnnt Funding of Costs (Re Actlvltl•s note 7) (see nrte 6) 2023 Tots CarE and 9JFPNt Awarentss Ralstrrfj & Ed￿￿on Researth for a Cure 40,826 158.820 6,931 10,583 3,536 47,757 192,337 22,934 247 458 Support ndlng of Corts (xe A¢tlvttle5 note 7) (M• not• 6) 2012 Totals Carè SuHyort Awareness Raisng & Rewrch for a Cure 31,802 65.467 16,155 21,313 47,957 103,849 17,C69 156 602 GRAP￿5 PAYABLE 2023 2022 Awaren￿ Ra￿ing & EdLKatk The totsl wants pakl to InstslutK￿s the yw was as fdlrths 2023 2022 European Caw (tynis)tK)n aobal Action on Men's Health 17,934 17,069 934

SIJPPORT cosrs 2023 2022 Bonk charyes Pen51ons Rent and rs Jnsuran Fee5 and substhptk 301 410 4.984 5,724 276 7,212 3Cfj 828 741 400 7.658 Sundrles Travel and meetlThJs staff trainirvj ConsiAtancy fees cOnfere￿e expe￿e5 IndepeTrdent examlnalhy fee PLcwntsro and 1 fees 333 52 20,600 2,146 5,100 4,9BO 732 £42 159 NEf INCOME {EXPENDmiRE) 2023 2022 Net Ir￿n￿[Expe￿i￿e) is stated after d￿rgIn￿{cre(lltJr1J).' IrthFendent Examiw s Fee £4 980 £5 100 TRumES' REMUNERATtON AND BEIIEFTts There We￿ no tDJstees' remuneration LY other beMfits lor tre ￿Or ended 31 December 2023 w for I year ended 31 Decemt 2022. There were Tr) tru5tees' expense5 pad the 31 CcemiEr 2023 nor for the ended 31 Decemter 2022. 10. STAFF COSTS 2023 2022 Wages and Salarfe5 Sccial Seojrity Costs Oth¥ PensK)n Costs 40,295 4,955 1.350 42.567 4,956 1,356 £46 600 £48 879

io. STAFF COSTS- ￿ntInUed 2023 2022 Arage monthly anpbyees The key management personnel of ￿ d)arty a￿ those havirrfJ a￿th￿ty responslbility for annlno, dlredlno (c￿￿11n0 the aetwitieg ol the dwrty. dlrecty or lThJifeLty, Ind¥Kllng any trLrstee of the charty and, In the case of the tharlty, Indth tt D￿rt¢rf of UK Operat)ns. Totsl emp b￿alts paid to kw marw9emw)t ptrsomel in the Fentyj amounted to £45.250 (2022.. £47,523), ii. COMPARATIVES FOR TrIE sfATEMEpif OF FINANCTAL AcfivmES Futhth Funth Tot•1 Fund# INCOME AMD ENDOWMENTS FROM Donathjrts Legades 90,094 other Tr>JlThJ ktivit*s Investrnent IrK 64.776 64,776 Totsl 154 92 EXPENDITiIRE ON Raising Funds 16.407 16.407 Char?table Activilierf Qre and Supp)r( AWa￿￿e$S Raising & Educati Researd) a Cure 47,957 103.849 47,957 103,849 Tot•1 NET INCOMEI(EXPEMDrnIRE) {18,117) (18.117) RECONCILIATION OF FUNDS Total Brought Fon¥ard 13.ICKJ 76,064 TOTAL FUNDS CARRIED FORWARD

THE HPV AND ANAL CANCER FOUNDATION UMrrED THEA END istD BER 12. TANGIBLE FIXED ASSErs Plant and Machinery COST At l January 2023 and 31 December 2023 DEPRECIATION At l January 2023 arnl 31 December 2023 NET BOOK VALUE At 31 DecernL￿r 2023 At 31 D￿ernber 2022 13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR 2023 2022 Gift Aid Re￿erable 831 14. CREDITORS: AMOUNTS FALUNG DUE WrnIIN ONE YEAR 2023 2022 Deferr8J Income Accrued Expenses 5,922 £10 663 27

AND ANAL ccouKrs DED 31 MBER 20 15. ANALYSIS OF IIEf ASSEfs BEfwEEN FUNDS Funds Funds 2023 2022 Current Assets Current Liabilities 272,675 13,ICK) 303,735 68,610 £281655 £13 ICQ £294 755 COMPARAIIVE Funds Funds 2022 2021 Current Assets Current Lk?billties 55,510 13.100 68,610 84,133 £13 Its) £57 947 16. MOVEMENT IN FUNDS At 31.12.23 Brought Incom• forward Expendlture Unrestrlcted Fund General FUTr 44,847 579,781 (342,973) 281,655 ReStrIct￿ Pundj Researth for a Cure 13,100 13,100 TOTAL FUNDS £579 781 £294 755 Net Movement In Funds, Ind￿ In the above are as f￿￿)w5. Exp￿dIturn At 31.12.22 forward Unrestrl<ed Funds General Fund 62,964 154,892 (173,009) 44,847 Restrlcted Funds Research for a Cure 13,1 13,1(Ki TOTAL FUNDS Capltal Fund The HPV arKI Anal CarKer FOundat￿n Limtted has shareholder cakitsl equal to £1 and is owned by HPV and Anal CarKer Foundathjn, a ￿lStered charity in the Unlted Ststes of America, EIN 27-3217520. Research for a Cure Fund The Fund was set up to award grants to research whKh wlll thn￿ devebwwit of efftttive fxeath)ents for anal arKI all HpV-re1a￿ cancer5.

NDA 17. RELATED PARTY DISCLOSURES No remunernthjn was to the tntstees in the ￿rI2022.. ENIL). A numter oftrustees gave donatth to the Chty durfrg the year. There ¥¥ve r￿1 condltions attathed to those dcfflaO￿s, The a)Jregate d￿311)n5 gl¥en to CN4rty by rdated parttes was £35.400. 18. GOING CONCERN The Trustee5 have Cons1￿ the effect of the current eo)norric dlmte on tharitvs act1￿1125. Tr Charty cufftndy IKJlits a comfortable of reseNes. aThJ ts l&ed costs are not 5b3nificant. It has tr* abilty to al￿n its artlOlles to the thl of reserves avaiL7b￿. Tr Tru#ee5 are Wmistc abcxrt the fiJndrat5ir•J Quu￿k for tl el￿ mcrth.